ASTRIA THERAPEUTICS INC
NASDAQ: ATXS (Astria Therapeutics, Inc.)
Last update: 2 hours ago12.72
-0.16 (-1.24%)
| Previous Close | 12.88 |
| Open | 12.92 |
| Volume | 774,187 |
| Avg. Volume (3M) | 2,123,450 |
| Market Cap | 726,119,168 |
| Price / Sales | 1.07 |
| Price / Book | 5.37 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 17.39 |
| Operating Cash Flow (TTM) | -96.14 M |
| Levered Free Cash Flow (TTM) | -62.11 M |
| Return on Assets (TTM) | -22.56% |
| Return on Equity (TTM) | -32.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Astria Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.50 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 106.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 30 Sep 2025 | 6,485,420 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 4,956,000 |
| Fcpm Iii Services B.V. | 30 Sep 2025 | 4,107,537 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 3,554,129 |
| Millennium Management Llc | 30 Sep 2025 | 3,034,527 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 2,761,861 |
| Vr Adviser, Llc | 30 Sep 2025 | 2,457,348 |
| Vivo Capital, Llc | 30 Sep 2025 | 1,552,685 |
| Rosalind Advisors, Inc. | 30 Sep 2025 | 1,542,520 |
| Nantahala Capital Management, Llc | 30 Sep 2025 | 1,069,530 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (Wedbush, 2.20%) | Hold |
| 13.00 (Jefferies, 2.20%) | Hold | |
| Median | 13.00 (2.20%) | |
| Average | 13.00 (2.20%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 11.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 15 Oct 2025 | 13.00 (2.20%) | Hold | 11.92 |
| Jefferies | 14 Oct 2025 | 13.00 (2.20%) | Hold | 11.61 |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update |
| 06 Nov 2025 | Announcement | Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart |
| 31 Oct 2025 | Announcement | Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting |
| 14 Oct 2025 | Announcement | BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile |
| 14 Oct 2025 | Announcement | BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |